Company Description
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide.
The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.
Its marketplace offers human biospecimens, including Biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; Solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and Hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types.
The company serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions.
iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jun 17, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Robert Lim |
Contact Details
Address: 8 Cabot Road Woburn, Massachusetts 02420 United States | |
| Phone | 781 301 6700 |
| Website | ispecimen.com |
Stock Details
| Ticker Symbol | ISPC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001558569 |
| CUSIP Number | 45032V108 |
| ISIN Number | US45032V1089 |
| Employer ID | 27-0480143 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Robert Bradley Lim | Chief Executive Officer, Treasurer, Secretary and Director |
| Katharyn Field | President |
| Yuying Liang | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | PRE 14A | Other preliminary proxy statements |
| Aug 7, 2025 | 8-K | Current Report |
| Aug 6, 2025 | D | Notice of Exempt Offering of Securities |
| Aug 5, 2025 | 8-K | Current Report |
| Jul 25, 2025 | 8-K | Current Report |
| Jul 25, 2025 | 424B4 | Prospectus |
| Jul 23, 2025 | EFFECT | Notice of Effectiveness |
| Jul 10, 2025 | 8-K | Current Report |
| Jul 8, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 27, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |